These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16763226)

  • 1. Switching statins.
    Moon JC; Bogle RG
    BMJ; 2006 Jun; 332(7554):1344-5. PubMed ID: 16763226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching statins: cost of simvastatin is overestimated.
    Ashcroft JS
    BMJ; 2006 Jun; 332(7556):1512. PubMed ID: 16793831
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug use review matters.
    Mueting M
    Nebr Nurse; 2007; 40(3):28. PubMed ID: 17915614
    [No Abstract]   [Full Text] [Related]  

  • 4. The paradigm of stains: will the lower cost of generics translate into health gains?
    Seabra-Gomes R
    Rev Port Cardiol; 2007 May; 26(5):497-501. PubMed ID: 17691276
    [No Abstract]   [Full Text] [Related]  

  • 5. Zero copayment for generic statins could save billions.
    Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2010; 10(6):369-82. PubMed ID: 21090830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
    J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.
    Godman B; Sakshaug S; Berg C; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):121-9. PubMed ID: 21351864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.
    Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; McGinn D; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahović-Palčevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):707-22. PubMed ID: 21155704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of reference-pricing systems in Europe: a literature review and case studies.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
    Ol'binskaia LI; Danilogorskaia IuA
    Ter Arkh; 2003; 75(12):47-50. PubMed ID: 14959470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
    Tinetti ME
    N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching statins: how to do it without tears and to benefit the NHS.
    Lau T
    BMJ; 2006 Jun; 332(7556):1513. PubMed ID: 16793835
    [No Abstract]   [Full Text] [Related]  

  • 16. How should we balance individual and population benefits of statins for preventing cardiovascular disease?
    Hingorani AD; Hemingway H
    BMJ; 2010 Jan; 342():c6244. PubMed ID: 21270079
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic atorvastatin and health care costs.
    Jackevicius CA; Chou MM; Ross JS; Shah ND; Krumholz HM
    N Engl J Med; 2012 Jan; 366(3):201-4. PubMed ID: 22149736
    [No Abstract]   [Full Text] [Related]  

  • 18. To switch (statins) or not to switch? That is the question.
    Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Dec; 11(18):2943-6. PubMed ID: 20958109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.
    Godman B; Schwabe U; Selke G; Wettermark B
    Pharmacoeconomics; 2009; 27(5):435-8. PubMed ID: 19586083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.